Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy.

Details

Serval ID
serval:BIB_3204412D13DD
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy.
Journal
Biochemical pharmacology
Author(s)
Jandus C., Simon H.U., von Gunten S.
ISSN
1873-2968 (Electronic)
ISSN-L
0006-2952
Publication state
Published
Issued date
15/08/2011
Volume
82
Number
4
Pages
323-332
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
The immune system must be tightly held in check to avoid bystander tissue damage as well as autoreactivity caused by overwhelming immune reactions. A novel family of immunoregulatory, carbohydrate-binding receptors, the Siglecs (sialic acid binding immunoglobulin-like lectins), has received particular attention in light of their capacity to mediate cell death, anti-proliferative effects and to regulate a variety of cellular activities. Siglec receptors are mainly expressed on leukocytes in a cell type-specific and differentiation-dependent manner. Siglecs might potentially be exploited as targets of novel immune- and glycotherapeutics for cell-directed therapies in autoimmune and allergic diseases, as well as in haematologic malignancies. Here we present novel insights on structural and functional characteristics, expression patterns and evolutionary aspects of Siglecs and their ligands. Pharmacological strategies using Siglec agonistic cross-linking therapeutics, such as monoclonal or engineered antibodies, intravenous immunoglobulin (IVIG), or glycomimetics are discussed. Modulation of immune responses by targeting Siglecs using agonistic or antagonistic therapeutics may have important clinical implications and may pave the way for novel pharmacological avenues for the treatment of autoimmune and allergic diseases or for tumor immunotherapy.

Keywords
Animals, Antibodies, Monoclonal/metabolism, Antibodies, Monoclonal/therapeutic use, Antigens, CD/immunology, Antigens, CD/metabolism, Antigens, Differentiation, Myelomonocytic/immunology, Antigens, Differentiation, Myelomonocytic/metabolism, Autoimmune Diseases/immunology, Autoimmune Diseases/metabolism, Autoimmune Diseases/therapy, Clinical Trials as Topic/methods, Drug Delivery Systems/methods, Hematologic Diseases/immunology, Hematologic Diseases/metabolism, Hematologic Diseases/therapy, Humans, Immunotherapy/methods, Immunotherapy/trends, Inflammation Mediators/agonists, Inflammation Mediators/pharmacology, Inflammation Mediators/physiology, Lectins/agonists, Lectins/chemistry, Lectins/physiology, Sialic Acid Binding Ig-like Lectin 2/immunology, Sialic Acid Binding Ig-like Lectin 2/metabolism, Sialic Acid Binding Ig-like Lectin 3, Sialic Acid Binding Immunoglobulin-like Lectins, Sialic Acids/agonists, Sialic Acids/chemistry, Sialic Acids/metabolism
Pubmed
Create date
11/02/2017 0:24
Last modification date
20/08/2019 14:17
Usage data